Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents

Clinical Pharmacokinetics

Volumn 35, Issue 4, 1998, Pages 275-291

  Hsu, Ann ^a   Granneman, G Richard ^a   Bertz, Richard J ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIVIRUS AGENT; CLARITHROMYCIN; CYTOCHROME P450; DESIPRAMINE; GLUCURONOSYLTRANSFERASE; INDINAVIR; KETOCONAZOLE; NELFINAVIR; OROSOMUCOID; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; PRIORITY JOURNAL;

ANIMALS; ANTI-HIV AGENTS; DRUG INTERACTIONS; HIV PROTEASE INHIBITORS; HUMANS; RITONAVIR;

EID: 0031751330     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199835040-00002     Document Type: Article

References (129)

1. 2 symmetric inhibitors of HIV protease. J Med Chem 1990; 33: 2687-9
2. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 1988; 85: 4686-90
3. Carpenter CJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA panel. JAMA 1997; 277: 1962-9
4. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12 (5): F9-F14
5. Montaner J, Demasi R, Hill A, et al. Validation of HIV-1 RNA and CD4 count as surrogate markers in the CAESAR trial [abstract 207]. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection; 1997 Oct 11-15; Hamburg, Germany
6. Ruiz NM, Manion DJ, Labriola DF, et al. Demographic and laboratory predictors of virologic treatment failures in patients achieving viral load reductions to below quantifiable levels (BQL) by Amplicor assay receiving indinavir +/- DMP 266 (efavirenz) [abstract 908]. Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection; 1997 Oct 11-15; Hamburg, Germany
7. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD-4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-6
8. Perelson AS, Neumann AU, Markowitz M, et al. HIV-1 dynamics in vivo: vision clearance rate, infected cell lifespan, and viral generations. Science 1995; 271: 1582-6
9. Mulder J, McKinney N, Christpherson C, et al. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32: 292-300
10. Pachl C, Todd JA, Kern DG, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 446-54
11. CAESAR Coordinating Committee. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-21
12. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-90
13. Delta Coordinating Committee. Delta: a randomized double-blind trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-91
14. Lalezari J, Haubrich R, Burger H, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir (invirase, SQV) plus Hivid (zalcitabine, ddC) [abstract LB.B.6033]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
15. Cameron DW, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with RTV, update [abstract Mo.B.411]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
16. Danner SA, Carr A, Leonard JM, et al. Safety, pharmacokinetics, and preliminary efficacy of RTV, an inhibitor of HIV-1 protease. N Engl J Med 1995; 333: 1528-33
17. Markowitz M, Saag M, Powderly W, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treal HIV-1 infection. N Engl J Med 1995; 333: 1534-9
18. Lalezari J, Haubrich R, Burger H, et al. Improved survival and decreased progression of HIV in patients treated with saquinavir (invirase, SQV) plus hivid (zalcitabine, ddC) [abstract LB.B.6033]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
19. Cameron DW, Japour A, Mellors J, et al. Antiretroviral safety and durability of ritonavir (RIT)-saquinavir (SQV) in protease inhibitor-naive patients in year two of follow-up [abstract 388]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
20. Shapiro JM, Winters MA, Stewart F, et al. The effect of high dose saquinavir on viral load and CD4+ T-cell counts in HIV infected patients. Ann Intern Med 1996; 124 (12): 1039-50
21. Acosta EP, Henry K, Weller D, et al. Indinavir pharmacokinetics and relationships between exposures and antiviral effect [abstract A-15]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
22. Drusano GL, Sadler BM, Millard J, et al. Pharmacodynamics of 141W94 as determined by short term change in HIV RNA: Influence of viral isolate baseline EC50 [abstract A-16]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
23. Burger DM, Koopmans PP, Brinkman K, et al. Therapeutic drug monitoring of the HIV-Protease inhibitor Indinavir [abstract A-19]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
24. Kempf DL, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus by coadministration with ritonavir. Antimicrob Agents Chemother 1997; 41 (3): 654-60
25. Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 1997 Mar; 11 (4): F29-33
26. Hsu A, Granneman GR, Japour A, et al. Evaluation of potential ritonavir and indinavir combination BID regimens [abstract A-57]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
27. Kerr B, Lee C, Yuen G, et al. Overview of in-vitro and in vivo drug interaction studies of nelfinavir mesylate (NFV), a new HIV-1 protease inhibitor. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
28. Crixivan™ package insert. Merck and Co., Inc., 1996
29. Viracept® package insert. Agouron Pharmaceuticals, Inc., 1997
30. Invirase™ package insert. Roche Laboratories, Inc., 1996
31. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A 1995; 92: 2484-8
32. Norvir™ package insert. Abbott Laboratories, 1998
33. Fortovase™ package insert. Roche Laboratories, Inc. 1998
34. Denissen JF, Grabowski BA, Johnson MK, et al. Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos 1996; 25 (4): 489-501
35. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277 (1): 423-31
36. Hsu A, Granneman GR, Witt G, et al. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 1997; 41 (5): 898-905
37. Flexner C, Hsu A, Kerr B, et al. Steady-state pharmacokinetic interactions between ritonavir (RTV), nelfinavir (NFV), and the nelfinavir active metabolite M8 (AG1402). Submitted. 12th World Congress on AIDS; 1998 Jun 28-Jul 3; Geneva
38. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers. Br J Clin Pharmacol. 1998; 46 (2): 111-6
39. Hsu A, Granneman GR, Witt G, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [abstract Mo.B.1200]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
40. Cato III A, Qian J, Hsu A, et al. Pharmacokinetics of ritonavir and zidovudine in human immunodeficiency virus-infected patients. Antimircob Agents Chemother 1998; 42 (7): 1788-93
41. Zhang MH, Pithavala YK, Lee CA, et al. Apparent genetic polymorphism in nelfinavir metabolism: evaluation of clinical relevance. 12th International Symposium on Microsomes and Drug Oxidation; 1998 Jul 20-24; Montpellier, France
42. Kumar GN, Grabowski B, Lee R, et al. Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538). Drug Metab Dispos 1996; 24 (5): 615-7
43. Woolley J, Studenberg S, Boehlert C, et al. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor 141W94 [abstract A-60]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997 Sep 28-Oct 1; Toronto
44. Inaba T, Fischer N, Riddick DS, et al. HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol Lett 1997; 93: 215-9
45. Chiba M, Hensleigh M, Nishime JA, et al. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Disp 1996; 24 (3): 307-14
46. Wu EY, Sandoval TM, Lee CA, et al. In vitro metabolism studies with the HIV-1 protease inhibitor, viracept (AG-1343). ISSX proceedings. 10: 326. 7th North American ISSX Meeting; 1996 Oct 20-24; San Diego
47. Livington DJ, Pazhanisamy S, Porter DJ, et al. Weak binding of VX-478 to human plasma proteins and implications for antihuman immunodeficiency virus therapy. J Infect Dis 1995; 172 (5): 1238-45
48. Polk RE, Israel DS, Patron R, et al. Pharmacokinetic (PK) interaction between 141W94 and rifabutin (RFB) and rifampin (RFP) after multiple-dose administration [abstract 340]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
49. McDowell JA, Sadler BM, Millard J, et al. Evaluation of potential pharmacokinetic (PK) drug interaction between 141W94 and 1592U89 in HIV+ patients [abstract A-62]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
50. Adkin JC, Faulds D. Amprenavir. Drugs 1998; 55 (6): 837-42
51. Kumar GN, Dykstra J, Jayanti V, et al. Potent inhibition of the in vitro human liver microsomal metabolism of the HIV-1 protease inhibitor ABT-378 by ritonavir: potential for a positive drug interaction [abstract 211]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
52. Lal R, Hsu A, Chen P, et al. Single dose pharmacokinetics of ABT-378 in combination with ritonavir [abstract I-194]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
53. Lal R, Hsu A, Granneman R, et al. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir [abstract 647]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
54. Baldwin JR, Borin MT, Wang Y, et al. Effect of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers [abstract 649]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
55. Borin MT, Carlson GF, Wang Y, et al. Single-Dose safety, tolerance, and pharmacokinetics of PNU-140690, a new HIV protease inhibitor, in healthy volunteers [abstract I-195]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
56. Borin MT, Wang Y, Schneck DW, et al. Multiple-dose safety, tolerance, and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers [abstract 648]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
57. Cato III A, Bertz RJ, Cao G, et al. Evaluation of the role of CYP3A inhibition in food and formulation effects on ritonavir absorption. 7th North America ISSX Annual Meetings; 1996 Oct 20-24; San Diego
58. Bertz RJ, Shi H, Cavanaugh JH, et al. Effect of three vehicles, Advera®, Ensure®, and chocolate milk, on the bioavailability of an oral liquid formulation of ritonavir [abstract A-5]. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996 Sep 15-18; New Orleans
59. Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998; 42 (2): 332-8
60. Abbott Laboratories, 1996-1998 (Data on file)
61. Farthing C, Japour A, Cohen C, et al. Cerebrospinal fluid (CSF) and plasma HIV RNA suppression with ritonavir (RIT)-saquinavir (SQV) in protease inhibitor naive patients [abstract LB-3]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
62. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276 (1): 960-4
63. Shimada T, Yamazaki H, Mimura M, et al. Inter-individual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-23
64. Bertz RJ, Cao G, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of desipramine [abstract Mo.B.1201]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
65. Hsu A, Granneman RG. Kinetics of ABT-538, a protease inhibitor, in humans after single oral rising doses [abstract PPDM 8272]. Pharm Res 1994; 11: S400
66. Hsu A, Granneman GR, Cao G-L, et al. Pharmacokinetic interactions between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother. In press
67. Hicks C, Lehman L, Eron, et al. Safety and efficacy of ritonavir administered at two potentially maximum tolerated doses [abstract Mo.B. 415]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
68. Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 1979; 24: 316-23
69. Decks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277 (2): 145-53
70. Muller BU, Zuckerman J, Nelson RP, et al. A phase I/II study of protease inhibitor ritonavir in children with human immunodeficiency virus infection. J Pediatr 1998 Mar; 101 (3 Pt 1): 335-43
71. Yogev R, Stanley K, Nachman SA, et al. Virologic efficacy of ZDV +3TC versus d4T + RTV versus ZDV + 3TC +RTV in stable antiretroviral experienced HIV-Infected children. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
72. Hsu A, Cameron DW, Valdes J, et al. Ritonavir pharmacokinetics in HIV-infected patients with underlying hepatic disease 1998 [abstract 359]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
73. Quellet D, Hsu A, Quian J, et al. Assessment of the effect of fluoxetine on the pharmacokinetics of ritonavir. Antimicrob Agents Chemother. In press
74. Bertilsson L, Lou Y-Q, Du Y-L, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51: 388-97
75. Molla A, Granneman GR, Sun E, et al. Recent developments in HIV protease inhibitor therapy. Antiviral Res 1998. In press
76. Molla A, Chernyavskiy T, Vasavanonda S, et al. Synergistic anti-HIV activity of ritonavir and other protease inhibitors in the presence of human serum. 12th World Congress on AIDS; 1998 Jun 28-Jul 3; Geneva
77. Hsu A, Granneman GR, Molla A, et al. Ritonavir-containing dual protease inhibitor regimens may have synergistic antiviral effects in patients - based on in vitro model. 12th World Congress on AIDS; 1998 Jun 28-Ju1 3; Geneva
78. Lazdins JK A, Mestan J, Goutte G, et al. In vitro effect of alacid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997; 175: 1063-70
79. Molla A, Korneyeva M, Cao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996; 2 (7): 760-6
80. Cato A, Cavanaugh JH, Shi H, et al. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 1998; 63: 414-21
81. Ouellet D, Hsu A, Granneman GR, et al. Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther. In press
82. Bertz R, Wong C, Carothers L, et al. Evaluation of the pharmacokinetics of multiple dose ritonavir and ketoconazole in combination. Clin Pharmacol Ther 1998; 63: 230
83. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453-64
84. Frye R, Bertz RJ, Granneman GR, et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam [abstract A-59]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
85. Hsu A, Granneman GR, Carothers L, et al. Ritonavir does not increase methadone exposure in healthy volunteers [abstract 342]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
86. Sun E, Heath-Chiozzi M, Cameron DW, et al. Concurrent ritonavir and rifabutin increases risk of rifabutin-associated adverse events [abstract Mo.B. 171]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
87. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibitors of alprazolam metabolism in film: effect of serotonin-reuptake inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31
88. Iribarne C, Berthou F, Baird S, et al. Involvment of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9: 365-73
89. Iribarne C, Dreano Y, Bardou LG, et al. Interaction of methadone with substrates of human hepatic cytochrome P450 3A4. Toxicol 1997; 117; 13-23
90. Guibert A, Furla V, Martino J, Taburet AM. In vitro effect of HIV protease inhibitors on methadone metabolism [abstract A-58]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
91. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994; 46: 35-9
92. Hossain M, Wright E, Baweja R, et al. Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharm Res 1997; 14: 309-15
93. Cobb M, Desai J, Brown LS, et al. The effect of fluconazole on the clinical pharmacokinetics of methadone [abstract Mo.B.1196]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
94. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32 (3): 210-58
95. max and Km values: implications for clinical correlation. J Pharmacol Exp Ther 1997; 282 (1): 391-6
96. Bertz RJ, Cao G, Cavanaugh JH, et al. Effect of ritonavir on the pharmacokinetics of trimethoprim/sulfamethoxazole [abstract Mo.B.1197]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
97. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36: S8-13
98. Fiske WD, Benedek IH, Kornhauser DM, et al. Pharmacokinetics of efavirenz (EFV) and ritonavir (RIT) after multiple oral doses in healthy volunteers. Submitted. 12th World Congress on AIDS; 1998 Jun 28-Jul 3; Geneva
99. Cato III A, Cao G, Hsu A, et al. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab Dispos 1997; 25 (9): 1104-6
100. Baciewicz AM, Self TH. Rifampin drug interactions. Arch Intern Med 1984; 144: 1667-71
101. Bjornsson T, Chiou R, Deutsch P, et al. Pharmacokinetics of indinavir. Pharm Res 1996; 13 (9): S485
102. Hsu A, Granneman GR, Sun E, et al. Assessment of single- and multiple-dose interactions between ritonavir and saquinavir [abstract LB.B 6041]. XI International Conference on AIDS; 1996 Jul 7-12; Vancouver
103. Hsu A, Granneman GR, Heath-Chiozzi M, et al. Indinavir can be given with regular meals when taken with ritonavir. 12th World Congress on AIDS; 1998 Jun 28-Jul 3; Geneva
104. Zhang K, Wu E, Patick A, et al. Plasma metabolites of nelfinavir, a potent HIV protease inhibitor, in HIV positive patients: quantitation by LC-MS/MS and antiviral activities. 11: 128. 6th European ISSX Meeting; 1997 Jun 30-Jul 3; Gothenburg, Sweden
105. Cato A, Qian J, Carothers, L, et al. Pharmacokinetic interactions between ritonavir and didanosine when administered concurrently to HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 466-72
106. ™ package insert. Pharmacia & Upjohn, 1998
107. Morse GD, Shelton MJ, Hewitt RG, et al. Ritonavir (RIT) pharmacokinelics (PK) during combination therapy with delavirdine (DLV) [abstract 343]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
108. Shelton MJ, Hewitt RG, Adams JM, et al. Delavirdine (DLV) mesylate pharmacokinetics (PK) during combination therapy with ritonavir (RIT) [abstract A-63]. 37th Interscience Conference on Antimicrobial Agents and Chemothetapy; 1997 Sep 28-Oct 1; Toronto
109. ™ Package Insert. Raxane Laboratories, 1998
110. Murphy R, Gagnier P, Lamson M, et al. Effect of nevirapine (NVP) on pharmacokinetics (PK) of indinavir (IDV) and ritonavir (RTV) in HIV-1 patients [abstract 374]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26: Washington, DC
111. Fiske WD, Benedek IH, White SJ, et al. Pharmacokinetic interaction between DMP 266 and nelfinavir mesylate (NFV) in healthy volunteers [abstract I-174]. 37th Interscicnce Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
112. Cox SR, Schneck DW, Herman BD, et al. Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers [abstract 345]. 5th Conference on Retroviruses and Opportunistic Infections: 1998 Feb 1-5; Chicago
113. Workman C, Musson R, Dyer W, et al. Novel double protease combinations-combining indinavir (IDV) with ritonavir (RTV): results from first study. 12th World Congress on AIDS; 1998 Jun 28-Jul 3; Geneva
114. Chong KT, Pagano PJ. In vitro combination of PNU140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrob Agents Chemother 1997; 41: 2367-73
115. Dudley MN. Clinical pharmacokinetics of nucleoside antiviral agents. J Infect Dis 1995; 171 Suppl. 2: S99-112
116. Knupp CA, Graziano FM, Dixon RM, et al. Pharmacokinetic interaction study of didanos?ine and ranitidine in patients seropositive for human immunodeficiency virus. Antimicrob Agents Chemother 1992; 36: 2075-9
117. Cox SR, Ferry JJ, Batts DH, et al. Delavirdine (D) and marketed protease inhibitors (Pls): pharmacokinetic (PK) interaction studies in healthy volunteers [abstract 372]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
118. Erickson DA, Riske PS, Hattox SE, et al. Nevirapine hydroxylation, an in vitro probe for the simultaneous determination of CYP3A and CYP2B6 activity in human liver microsomes [abstract 98]. 8th North American ISSX Meeting; 1997 Oct 26-30; Hilton Head, South Carolina
119. Havlir D, Cheeseman SH, McLaughlin M, et al. High-Dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients iwth human immunodeficiency virus infection. J Infect Dis 1995; 171: 537-45
120. Merry C, Barry MG, Mulcahy FM, et al. The pharmacokinetics of nelfinavir alone and in combination with nevirapine [abstract 351]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
121. Skowron G, Leoung G, Dusek A, et al. Stavudine (d4T), nelfinavir (NFV) and nevirapine (NVP): preliminary safety, activity and pharmacokinetic (PK) interactions [abstract 350]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
122. Christ DD, Fiske WD, Grubb MF, et al. The novel non-nucleoside reverse transcriptase inhibitor DMP 266 produces autoinduction of metabolism in rats and rhesus monkeys [abstract 299]. 8th North American ISSX Meeting; 1997 Oct 26-30; Hilton Head, South Carolina
123. Grubb M, Rao GP, Christ DD. effects of non-nucleoside reverse transcriptase inhibitor DMP 266 on AZT glucuronidation in vitro [abstract 188]. 8th North American ISSX Meeting; 1997 Oct 26-30; Hilton Head, South Carolina
124. Fiske WD, Mayers D, Wagner K, et al. pharmacokinetics of DMP 266 and indinavir multiple oral doses in HIV-1 infected individuals [abstract 568]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC
125. Piscitelli S, Vogel S, Sadler B, et al. Effect of efavirenz (DMP 266) on the pharmacokinetics of 141W94 in HIV-infected patients [abstract 346]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago
126. Wacher VJ, Wu C-Y, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and p-glyeoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 1995; 13: 129-34
127. Washington CB, Duran GE, Sikic BI, et al. Saquinavir is a high affinity substrate for the multidrug transporter, P-glycoprotein. Clin Pharmacol Ther 1997; 61 (2): 193
128. Hoff T, Brandt T, Demmer A, et al. Interaction of HIV protease inhibitors with MDR1: competitive binding and resistance modulation [abstract I-111]. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto
129. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101 (2): 289-94